Loading...
•
Dec 31, 2023
Black Diamond Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $19.4 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $131.4 million as of December 31, 2023, which is expected to fund operations into the second quarter of 2025.
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC
Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC
Oral presentation at AACR annual meeting in April 2024 describing real world evidence of an evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 to benefit patients across multiple lines of therapy
Additional planned data releases for 2024 include GBM results for BDTX-1535 in Q2, and initial results for BDTX-4933 in non-G12C KRASm NSCLC in Q4
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Black Diamond expects its cash, cash equivalents and investments will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2025.